303149-14-6
基本信息
SNAP 37889
HT-2157(SNAP37889)
SNAP-37889 (HT-2157)
SNAP 37889, CID1471834
1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
1-PHENYL-3-[[3-(TRIFLUOROMETHYL)PHENYL]IMINO]-1H-INDOL-2-ONE
2H-Indol-2-one, 1,3-dihydro-1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-
物理化学性质
| 熔点 | 141-144 °C |
| 沸点 | 484.0±55.0 °C(Predicted) |
| 密度 | 1.29±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMF:30.0(Max Conc. mg/mL);81.89(Max Conc. mM) DMSO:44.0(Max Conc. mg/mL);120.11(Max Conc. mM) Ethanol:7.0(Max Conc. mg/mL);19.11(Max Conc. mM) |
| 酸度系数(pKa) | -0.36±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | Yellow to orange |
1-PHENYL-3-[[3-(TRIFLUOROMETHYL)PHENYL]IMINO]-1H-INDOL-2-ONE价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-100717 | 1-PHENYL-3-[[3-(TRIFLUOROMETHYL)PHENYL]IMINO]-1H-INDOL-2-ONE HT-2157 | 303149-14-6 | 1mg | 900元 |
| 2024/11/08 | HY-100717 | 1-PHENYL-3-[[3-(TRIFLUOROMETHYL)PHENYL]IMINO]-1H-INDOL-2-ONE HT-2157 | 303149-14-6 | 10mM * 1mLin DMSO | 2176元 |
| 2024/11/08 | HY-100717 | 1-PHENYL-3-[[3-(TRIFLUOROMETHYL)PHENYL]IMINO]-1H-INDOL-2-ONE HT-2157 | 303149-14-6 | 5mg | 2700元 |
常见问题列表
Galanin-3 receptor
HT-2157 (SNAP 37889) binds with high affinity to membranes from transiently transfected LMTK - cells expressing the human Gal 3 receptor (K i =17.44±0.01 nM; n>100) and is highly selective for Gal 3 over the Gal 1 and Gal 2 subtypes (K i >10,000 nM for each subtype; n=46 of each subtype). When tested for the antagonism of galanin-evoked inhibition of adenylyl cyclase, HT-2157 (0.1-10 μM) produces concentration-dependent rightward shifts of the concentration-effect curve to galanin.
The galanin-3 receptor antagonist, HT-2157 (SNAP 37889), reduces operant responding for ethanol in alcohol-preferring rats. The novel selective GALR3 antagonist, HT-2157, to reduce anxiety-like behaviour and voluntary ethanol consumption in the iP (alcohol-preferring) rat. Male iP rats treated with HT-2157 at a dose of 30 mg/kg (i.p.) do not show altered locomotor activity or changes in anxiety-like behaviour in the elevated plus maze or light-dark paradigms. Treatment with HT-2157 (30 mg/kg, i.p.) reduces operant responding for solutions containing ethanol, sucrose and saccharin. Collectively, results from the current study shows that HT-2157 (30 mg/kg, i.p.) is effective in reducing operant responding for ethanol, independent of a sedative effect.